ReviewOrphanet journal of rare diseases2016
The risks of overlooking the diagnosis of secreting pituitary adenomas.
Review in Orphanet journal of rare diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Application of artificial intelligence and radiomics in pituitary neuroendocrine and sellar tumors: a quantitative and qualitative synthesis.Neuroradiology · 2022Pooled it
- Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.Advances in therapy · 2021Pooled it
- Proteomic profile of bone in patients with acromegaly: new insights from a pilot exploratory study.Journal of endocrinological investigation · 2026Article
- Hyperthyroidism, acromegaly, and hyperprolactinemia in a patient with a mature plurihormonal PIT-1 lineage adenoma.JCEM case reports · 2026Article
- Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery -Who Is Referring Them?Clinical endocrinology · 2026Article
- Incidence and characterization of spontaneous pituitary neuroendocrine tumors in aged spontaneously hypertensive rats.Scientific reports · 2025Article
- Knowledge and attitudes of primary care physicians regarding acromegaly: a survey study with multinational participation.BMC primary care · 2024Article
- "The healthcare system did fail me repeatedly": a qualitative study on experiences of healthcare among Canadian women with Cushing's syndrome.BMC primary care · 2024Article
- Controlled Study of Pre- and Postoperative Headache in Patients with Sellar Masses (HEADs-uP Study).Endocrinology, diabetes & metabolism · 2024Article
- From Genes to Therapy: Pituitary Adenomas in the Era of Precision Medicine.Biomedicines · 2023Review
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Radiation therapy outcomes of patients with pituitary macroadenoma.Biomedical reports · 2023Article
- Process analysis of the patient pathway for automated data collection: an exemplar using pituitary surgery.Frontiers in endocrinology · 2023Article
- Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.Pituitary · 2022Article
- Current and Emerging Medical Therapies in Pituitary Tumors.Journal of clinical medicine · 2022Review
- EIF1A depletion restrains human pituitary adenoma progression.Translational oncology · 2022Article
- Article
- The Interdisciplinary Management of Newly Diagnosed Pituitary Tumors.Deutsches Arzteblatt international · 2021Review
- Patient-Identified Problems and Influences Associated With Diagnostic Delay of Acromegaly: A Nationwide Cross-Sectional Study.Frontiers in endocrinology · 2021Article
- Development and validation of a targeted gene sequencing panel for application to disparate cancers.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreting pituitary adenomas that cause acromegaly and Cushing's disease, as well as prolactinomas and thyrotroph adenomas, are uncommon, usually benign, slow-growing tumours. The rarity of these conditions means that their diagnosis is not familiar to most non-specialist physicians. Consequently, pituitary adenomas may be overlooked and remain untreated, and affected individuals may develop serious comorbidities that reduce their quality of life and life expectancy. Because many signs and symptoms of pituitary adenomas overlap with those of other, more common disorders, general practitioners and non-endocrinology specialists need to be aware of the "red flags" suggestive of these conditions. A long duration of active disease in patients with secreting pituitary adenomas is associated with an increased risk of comorbidities and reduced quality of life. Appropriate treatment can lead to disease remission, and, although some symptoms may persist in some patients, treatment usually reduces the incidence and severity of comorbidities and improves quality of life. Therefore, correct, early diagnosis and characterization of a pituitary adenoma is crucial for patients, to trigger timely, appropriate treatment and to optimize outcome. This article provides an overview of the epidemiology of hormonal syndromes associated with pituitary adenomas, discusses the difficulties of and considerations for their diagnosis, and reviews the comorbidities that may develop, but can be prevented, by accurate diagnosis and appropriate treatment. We hope this review will help general practitioners and non-endocrinology specialists to suspect secreting pituitary adenomas and refer patients to an endocrinologist for confirmation of the diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.